Key Details
Price
$253.00Last Dividend
$0.89Annual Revenue
$106.37 BAnnual EPS
$20.00Annual ROE
15.71%Beta
0.34Events Calendar
Next earnings date:
Jan 24, 2025Recent quarterly earnings:
Oct 30, 2024Recent annual earnings:
Jan 25, 2024Next ex-dividend date:
Dec 31, 2024Recent ex-dividend date:
Sept 30, 2024Next split:
N/ARecent split:
Aug 01, 1991Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
The healthcare sector, especially Pharmacy Benefit Managers (PBMs), is under bipartisan examination, causing a drop in stock prices for Humana and Cigna, which could be a chance for investors. President-elect Donald Trump's views on PBMs and new bipartisan laws suggest possible regulatory changes, leading to uncertainty for companies linked to PBMs. Even with recent financial challenges, Cigna and Humana are experiencing solid revenue growth, although short-term profits are affected by investment losses and increasing benefit costs.
Humana's stock has dropped by 18%, while the S&P 500 has gained 13.5%, mainly due to temporary problems with Medicare Advantage. Even with these short-term cost difficulties, Medicare Advantage is still expected to benefit the company in the long run, and the value of CenterWell coordinated care is not yet reflected in Humana's plans. I still recommend buying the stock, with a target price of $370, which suggests a potential increase of 28%.
Pomerantz LLP is looking into claims for investors of Humana Inc. ("Humana" or the "Company") (NYSE:HUM) as of November 26, 2024. Investors who are interested should reach out to Danielle Peyton at [email protected] or call 646-581-9980, ext.
Pomerantz LLP is looking into claims for investors of Humana Inc. ("Humana" or the "Company") (NYSE:HUM) as of November 20, 2024. Investors who are interested should reach out to Danielle Peyton at [email protected] or call 646-581-9980, ext.
Pomerantz LLP is looking into claims for investors of Humana Inc. ("Humana" or the "Company") (NYSE:HUM) as of November 17, 2024. Investors who are interested should reach out to Danielle Peyton at [email protected] or call 646-581-9980, ext.
Pomerantz LLP is looking into claims for investors of Humana Inc. ("Humana" or the "Company") (NYSE:HUM) as of November 17, 2024. Investors who are interested should reach out to Danielle Peyton at [email protected] or call 646-581-9980, ext.
Pomerantz LLP is looking into claims for investors of Humana Inc. ("Humana" or the "Company") (NYSE:HUM) as of November 16, 2024. Investors who are interested should reach out to Danielle Peyton at [email protected] or call 646-581-9980, ext.
Pomerantz LLP is looking into claims for investors of Humana Inc. ("Humana" or the "Company") (NYSE:HUM) as of November 16, 2024. Investors who are interested should reach out to Danielle Peyton at [email protected] or call 646-581-9980, ext.
Pomerantz LLP is looking into claims for investors of Humana Inc. ("Humana" or the "Company") (NYSE:HUM) as of November 15, 2024. Investors who are interested should reach out to Danielle Peyton at [email protected] or call 646-581-9980, ext.
Pomerantz LLP is looking into claims for investors of Humana Inc. ("Humana" or the "Company") (NYSE:HUM) as of November 15, 2024. Investors who are interested should reach out to Danielle Peyton at [email protected] or call 646-581-9980, ext.
FAQ
- What is the primary business of Humana?
- What is the ticker symbol for Humana?
- Does Humana pay dividends?
- What sector is Humana in?
- What industry is Humana in?
- What country is Humana based in?
- When did Humana go public?
- Is Humana in the S&P 500?
- Is Humana in the NASDAQ 100?
- Is Humana in the Dow Jones?
- When was Humana's last earnings report?
- When does Humana report earnings?
- Should I buy Humana stock now?